Setup

NeoGenomics is a $1.2B mid-cap clinical oncology lab transitioning from a volume model to higher-AUP NGS and MRD diagnostics. The Q1 2026 10-Q (filed April 28) showed +11.1% revenue growth and +27% adjusted EBITDA, and the stock moved +21% on the day. Worth looking at because four C-suite officers bought ≈$3.4M of stock between January and April — and the same 10-Q contains a quantitative contradiction with management's full-year guidance that the +21% move did not address.

What the filing says

Q1 revenue $186.7M (+11.1% YoY) modestly beat the implied ≈10% Q1 cadence. Adj EBITDA $9.0M (+27%) looked like a blowout, but ≈$4.3M of the YoY G&A reduction came from non-recurring legal cost savings (Goldenberg shareholder class action dismissed with prejudice March 13, 2026). Normalized EBITDA is ≈$4.7-5M — roughly in line with the Q1 cadence implied by the $55-57M FY guide.

Gross margin was 43.3% vs 43.6% Q1 2025 — down 30bps. The FY 2026 guide explicitly requires +100-120bps of gross margin expansion to deliver the $55-57M EBITDA target. Q1 went the wrong direction. Cost of revenue grew +$5.3M in supplies and +$5.0M in labor — volume-driven costs scaling proportionally with revenue, no operating leverage yet visible. For the FY guide to remain credible, Q2-Q4 must average +130-160bps of margin expansion.

Cash $146M (down from $160M Dec 31). $345M of 0.25% convertible notes due January 2028, conversion price $85.75 — deeply out of the money at current levels. CFO transition complete: Abhishek Jain in seat. Yfinance reports CEO Zook acquired 140,498 shares (≈$1.26M) on April 1; President Stone, ex-CFO Sherman, GC Olivo, and Officer Aunan made acquisitions in February-April totaling ≈$2.1M additional. Form 4 transaction codes still need primary-source verification.

What the market thinks

Mean analyst target $13.81 (range $11-17, 12 analysts, 2 Strong Buy / 4 Buy / 6 Hold). EV / FY2026E EBITDA is 25x; EV / FY2027E (assuming +25% EBITDA scaling) ≈20x — between mature labs (LH/DGX at 12-14x) and MRD growth (EXAS at 30-40x).

Options: P/C OI 0.21 (call-skewed), but put IV (107%) > call IV (89%) by 18pp — heavy call OI paired with elevated downside IV. Term structure 89.5% (15d) → 60.0% (113d, August expiry). Aug 21 catches the Q2 print (July 28) at materially compressed IV vs the front month. Short interest 7.1%, 5 days to cover.

Implied probability extracted from analyst targets and OTM call pricing: market gives 25-30% odds the stock reaches $13+ in 12 months. We estimate 35-45%. The implied gap is ≈10pp on bull resolution.

Why the gap exists

Three reasons.

First, the convergent positioning is fragmented across reporting silos. Insider buying, short setup, and analyst upgrades all have followers, but no single piece of research synthesizes them with the binary Q2 catalyst. Mid-cap with 12-analyst coverage isn't undercovered, but the Hold-to-Buy migration after Q1 has not yet chased the spot.

Second, the $345M convertible due January 2028 is approximately 19 months from refinancing conversation. At current EBITDA run-rate, refinancing terms would be punitive. Equity functions as a call option on EBITDA scaling enough to refi at par — but diagnostic-lab analysts don't model the company that way. The refi optionality is undiscussed.

Third, the Q1 gross margin print is a doorway state. Q1 went the wrong direction by 30bps; FY guide requires the opposite. The market is waiting on the Q2 print to resolve. We have a probability estimate (60% sequential improvement) but not certainty.

Risks (ranked)

1. Q2 gross margin compresses further (≤ 42.8%). Invalidates the FY guide and the operating-leverage thesis. Insider buys cushion the floor but don't override fundamentals.
2. Pharma services decline accelerates. "Macro clinical trial trends" per MD&A — no green-shoot language. Steeper decline pulls revenue below $793M floor.
3. Convertible refinancing terms. If 2027 EBITDA doesn't scale to $80M+, Jan 2028 refi happens at material discount or with equity dilution.
4. MolDX delays. RADAR ST H2 2026 indication approvals are latent upside. If both delay to 2027, the FY revenue upside disappears.
5. OIG investigation. $11.2M reserve, no resolution in sight. Tail risk if outcome is materially worse.

Catalysts

What would change our mind

• Q2 gross margin ≤ 42.8% — thesis broken
• Q1 earnings call commentary indicating Q1 margin compression is structural (mix-shift cost) rather than timing — material downgrade
• Form 4 verification showing the "Acquire" labels are mostly Code A (grants) or F (tax withhold) rather than Code P (open market) — collapses the strongest pattern signal to noise
• Insider net selling in next 90 days
• Both RADAR ST MolDX submissions delayed beyond 2026
• Pharma services 2026 decline > "low-to-mid single digit" guide

Evidence

LR signal: 1.3

Bullish but modest. The convergent setup at the cyclical trough is a real edge over consensus, but resisted >1.5 inflation: this is a +4.5% expected return at spot, with a binary catalyst in 90 days that resolves the doorway state. Bull P 40% vs market-implied 25-30% is ≈10pp edge — real, but not transformative. Form 4 verification and Q1 call transcript would tighten or weaken this read.